Tandem Investment Advisors Inc. Acquires 7,425 Shares of Stryker Corporation $SYK

Tandem Investment Advisors Inc. lifted its stake in Stryker Corporation (NYSE:SYK) by 2.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 280,444 shares of the medical technology company’s stock after acquiring an additional 7,425 shares during the period. Stryker makes up 3.5% of Tandem Investment Advisors Inc.’s portfolio, making the stock its 14th largest holding. Tandem Investment Advisors Inc. owned approximately 0.07% of Stryker worth $103,672,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker in the 2nd quarter worth approximately $26,000. Clayton Financial Group LLC acquired a new stake in shares of Stryker during the 3rd quarter valued at about $26,000. Elevation Point Wealth Partners LLC bought a new stake in Stryker in the second quarter valued at about $28,000. Sachetta LLC raised its position in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares in the last quarter. Finally, Kilter Group LLC bought a new position in Stryker during the second quarter worth about $29,000. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.90% of the stock is currently owned by corporate insiders.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat: Stryker reported adjusted Q4 EPS $4.47 and revenue $7.17B, topping consensus on both measures — a clear near‑term positive for revenue and profitability trends. Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Raised profit outlook: Management raised its full‑year profit forecast, citing strong implant and capital product demand — a catalyst for forward earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Solid full‑year momentum and guidance: FY2025 adjusted EPS and margins expanded (adjusted EPS $13.63; adjusted operating margin +100 bps year) and management guided 2026 organic net‑sales growth ~8.0%–9.5% with adjusted EPS $14.90–$15.10 — supports medium‑term upside. Stryker reports 2025 operating results and 2026 outlook
• Neutral Sentiment: Analyst/street context: Several firms maintain positive ratings (e.g., Piper Sandler reaffirmed a Buy), and sell‑side median targets remain well above the current price — supports sentiment but may already be priced in. Piper Sandler Remains a Buy on Stryker (SYK)
• Neutral Sentiment: Conference call / details ahead: Management held an earnings call and provided granular segment math and non‑GAAP reconciliations — useful for modeling but unlikely to shift the stock absent new guidance tweaks. Press release & conference details
• Negative Sentiment: Mixed segment dynamics: MedSurg & Neuro showed double‑digit growth, but spinal implants and some orthopaedics subcategories remain weak or volatile — a potential drag on sustained top‑line upside. Stryker Reports Strong Q4 and Full-Year 2025 Results
• Negative Sentiment: One‑offs and legacy charges: Prior goodwill impairments, tax adjustments and other special items still affect GAAP comparisons and introduce modeling uncertainty — some investors may be trimming positions until recurring earnings visibility is clearer. Full release: reconciliations and note on adjustments
• Negative Sentiment: Valuation and profit‑taking risk: SYK trades at a premium P/E (~46 on reported metrics) and recent insider selling activity may encourage short‑term profit‑taking despite the beat. Analyst comparison & metrics

Stryker Stock Performance

Stryker stock opened at $354.39 on Friday. The stock has a 50-day simple moving average of $359.38 and a 200 day simple moving average of $371.95. The stock has a market capitalization of $135.52 billion, a price-to-earnings ratio of 46.57, a P/E/G ratio of 2.29 and a beta of 0.89. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter last year, the company posted $4.01 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be given a $0.88 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio is presently 46.25%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. TD Cowen lowered Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective on the stock. in a research note on Monday. Evercore ISI set a $390.00 price target on Stryker in a research report on Monday, January 5th. Truist Financial dropped their price objective on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Citizens Jmp upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a research note on Friday, December 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $448.00 target price on shares of Stryker in a report on Friday, November 14th. Twelve investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $425.94.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.